JUN 17, 2017 09:50 AM PDT

New, Powerful Antibiotic Found in Soil

WRITTEN BY: Carmen Leitch
1 22 760

Soil has previously been the source of effective antibiotics, and now it has produced another. A new antibiotic called pseudouridimycin is made by a microbe that was collected in a soil sample taken in Italy. It effectively destroyed a broad spectrum of bacteria that are drug-sensitive and -resistant when assayed in vitro, and was able to cure a bacterial infection in a mouse model.

Structure of bacterial RNA polymerase, showing the binding sites for the new antibiotic pseudouridimycin (PUM) and the current antibacterial drug rifampin (Rif). PUM has a lower resistance rate and a smaller resistance target than Rif -- just 2 to 4 positions where alterations that result in PUM-resistance (blue) vs. 27 positions where alterations result in Rif-resistance (red) -- due to functional constraints on alteration of the binding site for PUM in the RNA polymerase active center. / Credit: David Degen and Richard H. Ebright (Rutgers University)

Researchers at Rutgers University-New Brunswick, the biotechnology company NAICONS Srl., and elsewhere reported the discovery in Cell, along with the mechanism behind the antibiotic’s action. The pseudouridimycin acts by inhibiting an enzyme, bacterial RNA polymerase, which makes RNA molecules in bacteria, essential for their survival.

Related: Antibiotics, Antibiotic-resistance Comes From the Same Place

Pseudouridimycin can mimic one of the ‘bases’ that RNA polymerase uses to build RNA molecules, nucleoside-triphosphate (NTP). As such it is a nucleoside-analog inhibitor of the polymerase. The drug attaches to the binding site used by NTP on the polymerase and stops new NTPs from binding there, stopping synthesis of the essential new RNA. Interestingly, this is the first nucleoside-analog inhibitor that is effective against bacterial RNA polymerase while leaving human RNA polymerase alone.

"Because the NTP binding site of bacterial RNA polymerase has almost exactly the same structure and sequence as the NTP binding sites of human RNA polymerases, most researchers thought it would be impossible for a nucleoside-analog inhibitor to inhibit bacterial RNA polymerase but not human RNA polymerases," said Richard H. Ebright, Board of Governors professor of chemistry and chemical biology and laboratory director at the Waksman Institute of Microbiology at Rutgers-New Brunswick, who led the research.

"But pseudouridimycin contains a side-chain that 'reaches' outside the NTP binding site and 'touches' an adjacent site that is present in bacterial RNA polymerase but not in human RNA polymerases and, as a result, it binds more tightly to bacterial RNA polymerase than to human RNA polymerases," Ebright said.

The antibiotic is an alternative to another commonly used drug that inhibits the same enzyme, a drug called rifampin. Since its mode of action is different from rifampin pseudouridimycin can be used in conjunction with it for a powerful, additive effect. Additionally, it has no cross-resistance with rifampin. Perhaps most critically, it has one-tenth the spontaneous resistance rate of rifampin.

The low rate of resistance is probably attributable to the fact that pseudouridimycin is a nucleoside-analog inhibitor. "The new antibiotic interacts with essential residues of the NTP binding site that cannot be altered without losing RNA polymerase activity and bacterial viability," Ebright explained. "Alterations of the NTP binding site that disrupt binding of the new antibiotic also disrupt RNA polymerase activity, resulting in dead bacteria, rather than resistant bacteria."

"Nucleoside-analog inhibitors that selectively inhibit viral nucleotide polymerases have had transformative impact on the treatment of HIV-AIDS and hepatitis C," said research co-leader Stefano Donadio, CEO of NAICONS Srl. "The anti-AIDS drugs Zidovudine, Videx, Zalcitabine, Lamivudine, and Viread are nucleoside-analog inhibitors, and the anti hepatitis-C drugs Solvadi and Harvoni are nucleoside-analog inhibitors."

"Nucleoside-analog inhibitors that selectively inhibit bacterial RNA polymerase could have a similarly transformative impact on the treatment of bacterial infections," Donadio continued.

"The discovery also underscores the importance of natural products in providing new antibiotics. Microbes have had had billions of years to develop 'chemical weapons' to kill other microbes,” he concluded.

Learn more about how nucleoside-analog inhibitors work form the video above, which uses AIDS drugs as an example.

Sources: AAAS/Eurekalert! via Rutgers University, Cell

 

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
MAY 30, 2018
Microbiology
MAY 30, 2018
'Innoculating' Newborns with Vaginal Fluids Found to be Unsafe
A lack of exposure to the vaginal canal does not account for the increased risk of later health problems for those born by C-section, researchers say.
JUN 20, 2018
Immunology
JUN 20, 2018
Immune System Accidentally Allows Meningitis Brain Infection
Several immune cells help fungi infect the brain and cause meningitis when they should be doing the exact opposite. From the University of Sydney, research
JUL 03, 2018
Immunology
JUL 03, 2018
Here's a Virus that Boosts the Immune System
There’s a new therapeutic approach to boosting the weakened immune system that develops naturally with age, but it’s anything but conventional.
JUL 04, 2018
Drug Discovery
JUL 04, 2018
Discovery of New Properties of an Anti-Tuberculosis Drug
  Investigators at the University of Otago found novel properties of a new anti-tuberculosis drug which may inspire more new drugs to treat tuberculos
JUL 14, 2018
Microbiology
JUL 14, 2018
Little-known STI may Become a Superbug
Scientists are growing concerned about a common sexually transmitted infection that not many people know about - MG or MGen.
AUG 11, 2018
Microbiology
AUG 11, 2018
A Microbrewery can Help us Monitor Radiation Exposure
This wearable technology is very sensitive, and can be used by workers that are at risk of radiation exposure.
Loading Comments...